Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-17T22:10:46.711Z Has data issue: false hasContentIssue false

Lithium Treatment in Post-psychotic Depression

Published online by Cambridge University Press:  29 January 2018

Daniel P. Van Kammen
Affiliation:
Unit on Neuropsychopharmacology, Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland 20014, USA
Paul E. Alexander
Affiliation:
Section on Psychiatry and Human Behavior, Brown University, Providence, Rhode Island 02906, USA
William E. Bunney Jr.
Affiliation:
Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland 20014, USA
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Six of eleven drug-free schizophrenic patients who were depressed following remission of their illness showed a significant decrease in their depressive symptomatology during a double-blind, placebo substitution lithium trial. Traditional indicators of prognosis did not predict lithium response in this small sample; the schizophrenic patients tolerated the lithium well. Lithium should be studied further in a larger patient sample as an adjunct in the treatment of post-psychotic depression, which frequently is treatment resistant.

Information

Type
Research Article
Copyright
Copyright © The Royal College of Psychiatrists 

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.